Linezolid in the treatment of implant-related chronic osteomyelitis

Clinical Orthopaedics and Related Research

Volumn 461, Issue , 2007, Pages 40-43

  Vercillo, Michael ^a   Patzakis, Michael J ^a   Holtom, Paul ^a   Zalavras, Charalampos G ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LINEZOLID; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ADULT; AGED; ARTHROPLASTY; CHRONIC OSTEOMYELITIS; CLINICAL ARTICLE; COMORBIDITY; CONFERENCE PAPER; DEBRIDEMENT; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; FRACTURE FIXATION; HUMAN; INFECTION CONTROL; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; PROSTHESIS INFECTION; RECURRENT INFECTION; TREATMENT OUTCOME; ARTICLE; BONE SCREW; CHRONIC DISEASE; DEVICE REMOVAL; INFECTION; JOINT PROSTHESIS; MIDDLE AGED; OSTEOMYELITIS; RETROSPECTIVE STUDY;

ACETAMIDES; AGED; ANTI-INFECTIVE AGENTS; CHRONIC DISEASE; COMORBIDITY; DEBRIDEMENT; DEVICE REMOVAL; FEMALE; HUMANS; INTERNAL FIXATORS; JOINT PROSTHESIS; MALE; MIDDLE AGED; OSTEOMYELITIS; OXAZOLIDINONES; PROSTHESIS-RELATED INFECTIONS; RETROSPECTIVE STUDIES;

EID: 34548322732     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/BLO.0b013e3180986d60     Document Type: Conference Paper

References (46)

1. Bassetti M, Di Biagio A, Cenderello G, Del Bono V, Palermo A, Cruciani M, Bassetti D. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA). J Infect. 2001;43:148-149.
2. Bibbo C, Patel DV, Tyndall WA, Sirkin MS, Chang V. Treatment of multifocal vancomycin-resistant Enterococcus faecium osteomyelitis in sickle cell disease: a preliminary report. Am J Orthop. 2003;32:505-509.
3. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36:159-168.
4. Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother. 2006;50:1599-1602.
5. Centers for Disease Control and Prevention (CDC). Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:624-626.
6. Centers for Disease Control and Prevention (CDC). Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep. 1997;46:813-815.
7. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999. MMWR Morb Mortal Wkly Rep. 2000;48:1165-1167.
8. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:565-567.
9. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK. Vancomycin-Resistant Staphylococcus aureus Investigative Team. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342-1347.
10. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448-451.
11. Cierny G, Mader JT, Pennick H. A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res. 2003;414:7-24.
12. Costerton JW. Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin Orthop Relat Res. 2005;437:7-11.
13. Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: its production and regulation. Int J Artif Organs. 2005;28:1062-1068.
14. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet. 2001;358:1975-1982.
15. Elting LS, Rubenstein EB, Kurtin D, Rolston KV, Fangtang J, Martin CG, Raad II, Whimbey EE, Manzullo E, Bodey GP. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer. 1998;83:2597-2607.
16. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46:2723-2726.
17. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA. 2001;285:1291.
18. Gristina AG, Costerton JW. Bacterial adherence to biomaterials and tissue. The significance of its role in clinical sepsis. J Bone Joint Surg Am. 1985;67:264-273.
19. Harwood PJ, Giannoudis PV. The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibioticresistant organisms. Expert Opin Drug Saf. 2004;3:405-414.
20. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40:135-136.
21. Holtom PD, Zamorano D, Patzakis MJ. Osteomyelitis attributable to vancomycin-resistant enterococci. Clin Orthop Relat Res. 2002;403:38-44.
22. Howden BP, Johnson PD, Charles PG, Grayson ML. Failure of vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2004;39:1544; author reply 1544-1545.
23. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38:521-528.
24. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis. 2006;42:389-391.
25. Lee E, Burger S, Shah J, Melton C, Mullen M, Warren F, Press R. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis. 2003;37:1389-1391.
26. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med. 1997;336:999-1007.
27. Li Z, Willke RJ, Pinto LA, Rittenhouse BE, Rybak MJ, Pleil AM, Crouch CW, Hafkin B, Glick HA. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy. 2001;21:263-274.
28. Livermore DM. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J Antimicrob Chemother. 2000;46:347-350.
29. Lovering AM, Zhang J, Bannister GC, Lankester BJ, Brown JH, Narendra G, MacGowan AP. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother. 2002;50:73-77.
30. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control. 1999;27:520-532.
31. Panlilio AL, Culver DH, Gaynes RP, Banerjee S, Henderson TS, Tolson JS, Martone WJ. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol. 1992;13:582-586.
32. Patzakis MJ, Zalavras CG. Chronic posttraumatic osteomyelitis and infected nonunion of the tibia: current management concepts. J Am Acad Orthop Surg. 2005;13:417-427.
33. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet. 1998;351:1212.
34. Polk RE. Red man syndrome. Ann Pharmacother. 1998;32:840.
35. Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother. 2002;50:747-750.
36. Rao N, Ziran BH, Hall RA, Santa ER. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res. 2004;427:67-71.
37. Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis. 2004;38:1058-1064.
38. Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection. 2004;32:8-14.
39. Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC, Ackman DM. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis. 1999;5:147-149.
40. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med. 1999;340:517-523.
41. Smith PF, Taylor CT. Vancomycin-induced neutropenia associated with fever: similarities between two immune-mediated drug reactions. Pharmacotherapy. 1999;19:240-244.
42. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR. Emergence of vancomycin resistance in Staphylococcus aureus: Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999;340:493-501.
43. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003;42:1129-1140.
44. Summers M, Misenhimer GR, Antony SJ. Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin. South Med J. 2001;94:353-355.
45. Tenover FC, McDonald LC. Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr Opin Infect Dis. 2005;18:300-305.
46. Till M, Wixson RL, Pertel PE. Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis. 2002;34:1412-1414.